Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation

Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation

Over the past several decades, advances in driven targeted therapy has revolutionized the management of oncogene-driven non-small cell lung cancer (NSCLC). However, there are only a few targeted drugs available for patients with rare mutations, such as BRAF, HER2, MET, RET, etc. In recent years, imm...

Full description

Bibliographic Details
Main Authors: Teng LI, Junling LI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-01-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
rare mutation
immune check point inhibitors
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.41

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.41

Similar Items